Somatropin - Grandis Biotech

Drug Profile

Somatropin - Grandis Biotech

Alternative Names: GrandiTropin T; InfiTropin CR

Latest Information Update: 16 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL
  • Developer Grandis Biotech; InfiMed Therapeutics; Kowa Pharmaceutical
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Growth disorders; Somatotropin deficiency; Turner's syndrome

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 16 Jul 2007 Discontinued - Phase-III for Growth disorders in European Union (Parenteral)
  • 16 Jul 2007 Discontinued - Preclinical for Somatotropin deficiency in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top